New shot aims to protect transplanted kidneys, replace daily pills
NCT ID NCT07412470
Summary
This study is testing if a new injectable drug called frexalimab can work as well as or better than the standard daily pills (tacrolimus) at preventing a patient's body from rejecting a new kidney transplant. It will involve about 526 adults receiving their first kidney transplant and will follow them for up to 5 years. The main goal is to see if the new treatment is as effective at keeping the new kidney healthy and the patient safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number : 0360003
RECRUITINGSydney, 2050, Australia
-
Investigational Site Number : 1560001
RECRUITINGShanghai, 200127, China
Conditions
Explore the condition pages connected to this study.